Securities code: 002589 securities abbreviation: Realcan Pharmaceutical Group Co.Ltd(002589) Announcement No.: 2022-012 Realcan Pharmaceutical Group Co.Ltd(002589)
Announcement on the resolutions of the 19th meeting of the 4th board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements and major omissions.
The notice of the 19th meeting of the Fourth Board of directors of Realcan Pharmaceutical Group Co.Ltd(002589) (hereinafter referred to as “the company” and ” Realcan Pharmaceutical Group Co.Ltd(002589) “) was sent in writing on February 11, 2022 and held in the conference room on the fourth floor of the company, No. 326 Airport Road, Yantai in the morning of February 17, 2022 by on-site and communication voting. The meeting was presided over by the chairman, Mr. Han Xu. There were 9 directors who should attend the meeting, 9 actually attended the meeting, and the company’s supervisors attended the meeting as nonvoting delegates. The meeting was held in accordance with the company law of the people’s Republic of China and other laws and regulations and the articles of association. After effective voting, the meeting formed the following resolutions:
1、 The proposal on the acquisition of 38.39992% equity and related party transactions of Tianjin guohuida Health Technology Co., Ltd. was deliberated and adopted.
The company plans to use its own funds to acquire 38.39992% equity of Tianjin guohuida Health Technology Co., Ltd. (hereinafter referred to as the “target company”) from Yantai huishuo enterprise management partnership (limited partnership), Taking the asset appraisal report on the value of all shareholders’ equity of Tianjin guohuida Health Technology Co., Ltd. (Beiya Shi Ping Bao Zi [2022] No. 01-042) involved in the proposed equity acquisition issued by Beiya Shi Asset Appraisal Office (special general partnership) on January 28, 2022 as the transaction basis and agreed by both parties through consultation, The audited amount of the underlying equity was RMB 148803.08, accounting for 23008% of the previous year’s net equity.
Related directors Zhang Renhua, Han Xu, Han Chunlin and Yang Bo avoided voting. The proposal was adopted by 4 votes in favor, 0 against and 1 abstention.
The specific contents of this proposal are detailed in the announcement on the proposed acquisition of equity and related party transactions. The independent directors of the company have issued prior approval opinions and relevant independent opinions on the proposal. For the specific contents, see China Securities News, securities times, Shanghai Securities News, securities daily and cninfo.com（ http://www.cn.info.com.cn. ）Disclosure of.
It is hereby announced. Documents for future reference: resolutions of the board of directors signed by the attending directors. Other documents required by Shenzhen Stock Exchange.
Realcan Pharmaceutical Group Co.Ltd(002589) board of directors
February 18, 2022
